← Leaderboards
Rubin M Tuder
University Of Colorado Denver
$19,596,454
Attributed
$20,673,447
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$20,673,447 · 20
By mechanism
R01$6,998,833 · 4
P01$6,191,664 · 7
P50$5,607,418 · 4
RC1$999,999 · 1
R21$707,199 · 2
R03$153,334 · 1
Top collaborators
- Mark W Geraci3 shared
- Jonathan Kirk Harris2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Vitaly Kheyfets$2,451,787
- Todd M Bull$3,801,048
- Angelo D'alessandro$12,761,823
- Kurt R Stenmark$22,132,904
- David Charles Irwin$10,493,842
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungInflammationMolecularCellsStructure Of Parenchyma Of LungInvestigationBaseBlood VesselsApoptosisTissuesInflammatoryPulmonary HypertensionOxidative StressLung DiseasesProteinsChronic Obstructive Airway DiseaseResearch PersonnelStructureTranslatingProgramsPhenotypeImageLeadGenomics
Grant awards (68)
Evaluation of the Dynamic Reciprocity Between Cells and the Vessel Matrix in Pulmonary Hypertension$429,154
P01 · FY2024 · HL · contact PI
Pathophysiology Core$175,179
P01 · FY2024 · HL · contact PI
Evaluation of the Dynamic Reciprocity Between Cells and the Vessel Matrix in Pulmonary Hypertension$437,913
P01 · FY2023 · HL · contact PI
Pathophysiology Core$178,753
P01 · FY2023 · HL · contact PI
Evaluation of the Dynamic Reciprocity Between Cells and the Vessel Matrix in Pulmonary Hypertension$437,913
P01 · FY2022 · HL · contact PI
Pathophysiology Core$178,753
P01 · FY2022 · HL · contact PI
Evaluation of the Dynamic Reciprocity Between Cells and the Vessel Matrix in Pulmonary Hypertension$437,913
P01 · FY2021 · HL · contact PI
Pathophysiology Core$178,753
P01 · FY2021 · HL · contact PI
Pathophysiology Core$398,710
P01 · FY2020 · HL · contact PI
Evaluation of the Dynamic Reciprocity Between Cells and the Vessel Matrix in Pulmonary Hypertension$398,709
P01 · FY2020 · HL · contact PI
Role of Inflammation in Schistosomiasis Pulmonary Hypertension$338,990
P01 · FY2018 · HL · contact PI
Pathology, Imaging and Flow Cytometry Core C$281,008
P01 · FY2018 · HL · contact PI
Role of Inflammation in Schistosomiasis Pulmonary Hypertension$338,990
P01 · FY2017 · HL · contact PI
Pathology, Imaging and Flow Cytometry Core C$281,008
P01 · FY2017 · HL · contact PI
Role of Inflammation in Schistosomiasis Pulmonary Hypertension$338,990
P01 · FY2016 · HL · contact PI
Pathology, Imaging and Flow Cytometry Core C$285,096
P01 · FY2016 · HL · contact PI
Role of Inflammation in Schistosomiasis Pulmonary Hypertension$338,990
P01 · FY2015 · HL · contact PI
RTP-801 in Cigarette Smoke-Emphysema$303,103
R01 · FY2015 · ES · contact PI
Pathology, Imaging and Flow Cytometry Core C$290,796
P01 · FY2015 · HL · contact PI
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer$580,374
R01 · FY2014 · CA · contact PI
RTP-801 in Cigarette Smoke-Emphysema$308,314
R01 · FY2014 · ES · contact PI
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer$564,154
R01 · FY2013 · CA
RTP-801 in Cigarette Smoke-Emphysema$311,963
R01 · FY2013 · ES · contact PI
Microbiome in COPD$169,456
R21 · FY2013 · HL · contact PI
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer$601,421
R01 · FY2012 · CA
RTP-801 in Cigarette Smoke-Emphysema$325,261
R01 · FY2012 · ES · contact PI
Microbiome in COPD$216,250
R21 · FY2012 · HL · contact PI
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer$602,705
R01 · FY2011 · CA
Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema$482,593
P50 · FY2011 · HL · contact PI
CORE--MOLECULAR PATHOLOGY$345,193
P50 · FY2011 · HL · contact PI
RTP-801 in Cigarette Smoke-Emphysema$332,120
R01 · FY2011 · ES · contact PI
MOLECULAR PATHOPHYSIOLOGY CORE$259,540
P50 · FY2011 · HL · contact PI
54th Annual Thomas L. Petty Aspen Lung Conference: COPD and Lung Cancer: Common P$15,000
R13 · FY2011 · HL · contact PI
Zipcode based nano-imaging of hypertensive pulmonary arteries$499,999
RC1 · FY2010 · HL · contact PI
Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema$482,352
P50 · FY2010 · HL · contact PI
CORE--MOLECULAR PATHOLOGY$336,631
P50 · FY2010 · HL · contact PI
MOLECULAR PATHOPHYSIOLOGY CORE$259,415
P50 · FY2010 · HL · contact PI
Microbiome in Chronic Obstructive Pulmonary Disease$76,542
R03 · FY2010 · HL · contact PI
Zipcode based nano-imaging of hypertensive pulmonary arteries$500,000
RC1 · FY2009 · HL · contact PI
Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema$479,551
P50 · FY2009 · HL · contact PI
CORE--MOLECULAR PATHOLOGY$329,845
P50 · FY2009 · HL · contact PI
MOLECULAR PATHOPHYSIOLOGY CORE$257,912
P50 · FY2009 · HL · contact PI
Microbiome in Chronic Obstructive Pulmonary Disease$76,792
R03 · FY2009 · HL · contact PI
Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema$466,958
P50 · FY2008 · HL · contact PI
CORE--MOLECULAR PATHOLOGY$323,002
P50 · FY2008 · HL · contact PI
MOLECULAR PATHOPHYSIOLOGY CORE$252,438
P50 · FY2008 · HL · contact PI
Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema$370,303
P50 · FY2007 · HL · contact PI
CORE--MOLECULAR PATHOLOGY$337,787
P50 · FY2007 · HL · contact PI
MOLECULAR PATHOPHYSIOLOGY CORE$271,634
P50 · FY2007 · HL · contact PI
Core--Molecular Pathology$238,747
P50 · FY2007 · HL · contact PI
Endothelial Cell Death in Emphysema$237,345
R01 · FY2007 · HL · contact PI
Endothelial Cell Death in Emphysema$98,925
R01 · FY2007 · HL · contact PI
Endothelial Cell Death in Emphysema$362,995
R01 · FY2006 · HL · contact PI
Endothelial Cell Death in Emphysema$372,061
R01 · FY2005 · HL
Rodent model of severe pulmonary hypertension$232,637
P01 · FY2005 · HL
Discovery of biomarkers of pulmonary hypertension$163,500
R21 · FY2005 · HL
Endothelial Cell Death in Emphysema$373,069
R01 · FY2004 · HL
Discovery of biomarkers of pulmonary hypertension$157,993
R21 · FY2004 · HL
ENDOTHELIAL CELL DEATH AND INFLAMMATION IN EMPHYSEMA$255,213
R01 · FY2003 · HL
Core--Molecular Pathology$113,517
P50 · FY2003 · HL
ENDOTHELIAL CELL DEATH AND INFLAMMATION IN EMPHYSEMA$255,213
R01 · FY2002 · HL
Rodent model of severe pulmonary hypertension$213,409
P01 · FY2002 · HL
ENDOTHELIAL CELL DEATH AND INFLAMMATION IN EMPHYSEMA$296,088
R01 · FY2001 · HL
VEGF PROTECTS AGAINST PULMONARY VASCULAR REMODELING$263,307
R01 · FY2001 · HL
Rodent model of severe pulmonary hypertension$0
P01 · FY2001 · HL
VEGF PROTECTS AGAINST PULMONARY VASCULAR REMODELING$255,637
R01 · FY2000 · HL
ENDOTHELIAL CELL DEATH AND INFLAMMATION IN EMPHYSEMA$239,389
R01 · FY2000 · HL
ENDOTHELIAL CELL DEATH AND INFLAMMATION IN EMPHYSEMA$60,176
R01 · FY2000 · HL